Source link : https://www.newshealth.biz/health-news/promising-os-at-5-years-with-chemo-free-combo-in-urothelial-cancer/
Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and meaningful survival in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, according to 5-year follow-up results from a phase Ib/II study presented at the recent European Society for Medical Oncology (ESMO) annual congress in Barcelona. In this exclusive MedPage […]
Author : News Health
Publish date : 2024-11-08 21:30:00
Copyright for syndicated content belongs to the linked Source.